T M M Inc (TMMI): Good work. Thank you.

Play Episode

6min

Proactive - Interviews for investors

Itaconix CEO on 2025 strategy and profitability goals

Itaconix PLC (AIM:ITX, OTCQB:ITXXF) CEO John Shaw joined Steve Darling from Proactive to provide an update on the company’s progress following its strategic restructuring and to discuss what lies ahead for 2025. Shaw highlighted that the company ended 2024 with strong momentum, achieving nearly $3.7 million in revenue in the second half, marking one of its highest-ever earnings periods. The restructuring initiative focused on enhancing profitability, with a significant emphasis on reshaping the customer base. Shaw noted, “We actually increased our gross profit margin from about 31% to almost 35% last year.” Despite experiencing lower revenue in some areas, the company was able to maintain steady gross profits due to its emphasis on margin improvement. Shaw also discussed significant product developments, including the launch of Itaconix TSI 422, a new detergent ingredient that is gaining traction in North America and Europe. He further explained how the SPARX program, introduced in October, is helping accelerate customer collaboration in key product categories, positioning the company for continued growth. In addition to product development, the company has made strategic investments in its operations, marketing, and regulatory capabilities to support its growth trajectory. Shaw expressed confidence in the company’s production team and infrastructure, stating, “We really have everything in place we need right now to have a great run over the next 24 months.” While tariffs remain a consideration, Shaw believes any impacts will be manageable, and in some cases, could even be beneficial to the company. #proactiveinvestors #itaconixplc #aim #itx #otcqb #itxxf #SustainableChemicals #CleanTech #TSI422 #SPARXProgram #SpecialtyChemicals #JohnShaw #InvestorUpdates #ProactiveInvestors #GreenChemistry #DetergentInnovation #GrossProfitMargins #RestructuringSuccess

Proactive - Interviews for investors

How Beforepay’s AI model drives strong returns

Beforepay Group Ltd Finance Manager Shreya Prakash talked with Proactive about the company’s dual focus on domestic consumer lending and enterprise software through its Carrington Labs division. She explained that Beforepay’s core product—a pay advance offering—provides short-term loans with a fixed 5% fee and no hidden costs, aiming to support Australians with transparent and ethical lending. Prakash said, “The most common reason people borrow from us is not because they want to go for a vacation... but to tide them over that short-term cash flow pinch.” She highlighted that this flagship product, launched in 2020, remains central to the business and differentiates itself through its ethical model and efficient cost structure. Carrington Labs, the company’s AI and analytics arm, is productising the risk models that power Beforepay and expanding operations in the US. Prakash noted that the company is writing around 40,000 loans with just 50 staff, underlining a strong operational efficiency. Billy Cheung, also from the finance team, added that Beforepay became profitable in the first half of FY23. He reported revenue approaching A$20 million and net profit of A$2.8 million in H1 FY25. Notably, the company reduced net defaults from around 3% to just 1.1%, attributing this to improved credit risk models. Cheung also mentioned growth in personal loan offerings and continued investment into Carrington Labs. While Beforepay’s main focus remains on the Australian market, the company is actively expanding Carrington Labs internationally, particularly in the US. Visit Proactive’s YouTube channel for more videos, and don’t forget to give the video a like, subscribe to the channel and enable notifications for future content. #Beforepay #ASXB4P #FintechAustralia #EthicalLending #PayAdvance #CarringtonLabs #AIinFinance #ConsumerLending #PersonalFinance #FinancialWellbeing #InvestorUpdate #ProactiveInvestors #FinanceInterview #ASXStocks #FintechNews

Proactive - Interviews for investors

Race Oncology launches Phase I RC220 trial in Australia

Race Oncology CEO and MD Daniel Tillett talked with Proactive about the opening of patient enrollment at the first Australian clinical site for the RC220 Phase I solid tumour trial. Tillett confirmed that the trial is now underway, with additional sites expected to follow soon. The focus of this early-stage study is to determine a safe and effective combination dose of RC220 with the chemotherapy drug doxorubicin. According to Tillett, “our drug has the advantage… not only does it improve the anti-cancer treatment, but it protects the heart, at least in animals and cells to date.” He noted the choice of Southside Cancer Centre as the initial site, citing the faster startup process compared to public hospitals. Other sites, including Gosford and Wyong, have also received ethics approval and are expected to join the trial following regulatory clearance. Tillett discussed the use of a Bayesian trial design, which allows quicker progression and minimises patient exposure to suboptimal doses. While this approach can introduce uncertainty in timelines, it is expected to be more beneficial overall for patients and the company. Early preclinical data has shown that RC220 can reduce doxorubicin-related toxicity while enhancing cancer treatment outcomes, a combination Tillett described as unique among current therapies. Beyond the trial, Race Oncology is conducting separate preclinical studies to identify the most effective drug combinations using RC220. Tillett noted that more updates on this work are expected in the coming months. Watch the full video to hear more from Daniel Tillett and stay informed on Race Oncology’s developments. ➡️ For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and hit the notification bell for future updates. #RaceOncology #RC220 #CancerResearch #ClinicalTrials #OncologyUpdates #Doxorubicin #CardioProtection #BayesianDesign #CancerTreatment #BiotechNews #ProactiveInve

Proactive - Interviews for investors

Titan Mining reports record 2024 production, expands resources

Titan Mining President Rita Adiani joined Steve Darling from Proactive to discuss the company’s year-end results, highlighting record production and strong financial performance in 2024. The company met the upper end of its production guidance, while costs were 10% lower than the low end of its all-in sustaining cost (AISC) guidance. In Q4 2024, Titan Mining produced 21.7 million pounds of payable zinc, marking a 56% increase compared to Q4 2023. Total full-year 2024 production reached 59.5 million pounds. The company also posted Q4 revenues of $26.3 million, representing a 318% increase from Q3 2024 and a 241% increase from Q4 2023. Adiani also shared updates on the company’s mineral resource expansion, noting that Titan completed an updated mineral resource estimate and extended the mine life for ESM’s zinc operations until 2033. The updated estimate reports a 22% increase in measured and indicated contained zinc pounds compared to the 2020 resource estimate. In addition to its zinc operations, Titan completed a maiden mineral resource estimate for the Kilbourne Graphite Project. The project now holds an open-pit constrained inferred mineral resource of 22 million U.S. short tons, with an average grade of 2.91% (Cg), containing 653,000 tons of graphite at a 1.50% cut-off grade. #proactiveinvestors #titanminingcorporation #tsx #ti #otcqb #timcf #TitanMining #ZincProduction #GraphiteMining #BatteryMetals #CriticalMinerals #MiningStocks #TSX #RitaAdiani #EVMaterials #GraphiteUSA #MiningExpansion #AgustaGroup #ProactiveInvestors

Followers	5
Posts	1062
Boards Moderated	0
Alias Born	06/26/2017

Volume:	13,990
Day Range:	0.01465 - 0.0154
Bid:	0.0126
Ask:	0.0163
Last Trade Time:	1:24:57 PM EDT
Total Trades:	3

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

TMMI Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free